gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · RANIHealthcarePharmaceuticals

Rani Therapeutics Holdings, Inc. Class A Common Stock (RANI)

$0.5728+3.06%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$0.55▼ 74.26% in range
Nov 3, 2025Low $0.55 · High $2.50Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Rani Therapeutics Holdings closed at $0.57 on Nov 4, up 3.06%, 77.1% below its 52-week closing high. Volume of 286.2K shares was 0.55× its 20-day average (below normal).

Split-adjusted performance: -30.9% over one month, -40.3% over six months, -73.4% over one year.

In the quarter ended Jun 30, 2026, revenue was $1.71M, with a net margin of -432.7%.

Short interest was 8.2M shares at the Oct 15 settlement, up 12.5% from the prior report (10.4% of float, 14.2 days to cover).

Market cap$66.1M115.4M shares
Revenue · quarter$1.7M—
Diluted EPS$-0.04—
P/E · TTM—P/S 13.6×
Net margin-432.7%Gross 100.0%
Dividend yieldNone
52-week range0.55 – 2.50−77.1% from high
Volume286.2K0.55× 20-day avg
Volatility · 60d63.6%Annualised
Short % of float10.4%14.2 days to cover
Net cash$53.4MCash $53.4M
Next earnings—Not scheduled
Split-adjusted performance
1W −6.9%1M −30.9%3M −26.7%6M −40.3%YTD −57.6%1Y −73.4%3Y −70.8%5Y −97.5%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum33
Revenue growth—
Net margin31
Value (low P/E)—
Size36

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short8.2M+12.5% vs prior
Days to cover14.2Settled Oct 15
% of float10.4%
Short vol. 10d51.9%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
RANIRani Therapeutics Holdings$0.5728+3.06%−40.3%—−432.7%—$66.1M
CINGCingulate$4.56−3.39%−14.4%———$66.3MCompare
CPIXCumberland Pharmaceuticals$4.44+3.02%+1.6%−56.3%−2569.0%—$66.5MCompare
FBIOFortress Biotech$1.97+1.55%−22.7%+14.0%−13.2%0.6$65.7MCompare
TENXTenax Therapeutics$1.81−1.63%−84.9%———$67.7MCompare
TELOTelomir Pharmaceuticals$0.8750−3.85%−34.7%———$64.5MCompare
CRBPCorbus Pharmaceuticals Holdings$3.57−7.75%−67.3%———$69.0MCompare
QUCYQuantum Cyber N.V$0.7430+2.65%————$62.5MCompare
SPROSpero Therapeutics$1.07+2.88%−57.7%−100.0%—8.4$62.3MCompare

News about Rani Therapeutics Holdings

All news →
Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq RulesGlobeNewswire Inc. · May 26, 2026▲ PositiveRani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline PrioritizationGlobeNewswire Inc. · Mar 25, 2026▲ Positive

Quick answers

What does Rani Therapeutics Holdings do?
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides.
What is RANI's market cap?
$66.12M, based on the Nov 4 close of $0.57.
Does Rani Therapeutics Holdings pay a dividend?
No regular cash dividend has been paid in the last year.
How much of RANI is sold short?
8.2M shares, 10.4% of float, as of Oct 15, 2026.
What sector is RANI in?
Healthcare, in the Pharmaceuticals industry.

About Rani Therapeutics Holdings

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

HQ: San Jose, CA69 employeesListed Jul 30, 2021ranitherapeutics.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology